Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Liver Fibrosis
Tingfen Li,Yongmin Yan,Bingying Wang,Hui Qian,Xu Zhang,Li Shen,Mei Wang,Ying Zhou,Wei Zhu,Wei Li,Wenrong Xu +10 more
808
TL;DR: Results suggest that hucMSC-Ex could ameliorate CCl4-induced liver fibrosis by inhibiting EMT and protecting hepatocytes, which provides a novel approach for the treatment of fibrotic liver disease.
read more
Abstract: Mesenchymal stem cells (MSCs) have been considered as an attractive tool for the therapy of diseases. Exosomes excreted from MSCs can reduce myocardial ischemia/reperfusion damage and protect against acute tubular injury. However, whether MSC-derived exosomes can relieve liver fibrosis and its mechanism remain unknown. Previous work showed that human umbilical cord-MSCs (hucMSCs) transplanted into acutely injured and fibrotic livers could restore liver function and improve liver fibrosis. In this study, it was found that transplantation of exosomes derived from hucMSC (hucMSC-Ex) reduced the surface fibrous capsules and got their textures soft, alleviated hepatic inflammation and collagen deposition in carbon tetrachloride (CCl4)-induced fibrotic liver. hucMSC-Ex also significantly recovered serum aspartate aminotransferase (AST) activity, decreased collagen type I and III, transforming growth factor (TGF)-β1 and phosphorylation Smad2 expression in vivo. In further experiments, we found that epithelial-to-mesenchymal transition (EMT)-associated markers E-cadherin-positive cells increased and N-cadherin- and vimentin-positive cells decreased after hucMSC-Ex transplantation. Furthermore, the human liver cell line HL7702 underwent typical EMT after induction with recombinant human TGF-β1, and then hucMSC-Ex treatment reversed spindle-shaped and EMT-associated markers expression in vitro. Taken together, these results suggest that hucMSC-Ex could ameliorate CCl4-induced liver fibrosis by inhibiting EMT and protecting hepatocytes. This provides a novel approach for the treatment of fibrotic liver disease.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Concise Review: MSC-Derived Exosomes for Cell-Free Therapy
TL;DR: T careful attention to detail in producing MSC exosomes may provide a new therapeutic paradigm for cell‐free MSC‐based therapies with decreased risk.
1.4K
Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper
Thomas Lener,Mario Gimona,Ludwig Aigner,Verena Börger,Edit I. Buzás,Giovanni Camussi,Nathalie Chaput,Devasis Chatterjee,Felipe A. Court,Hernando A. del Portillo,Lorraine O'Driscoll,Stefano Fais,Juan M. Falcón-Pérez,Ursula Felderhoff-Mueser,Lorenzo Fraile,Yong Song Gho,André Görgens,Ramesh C. Gupta,An Hendrix,Dirk M. Hermann,Andrew F. Hill,Fred H. Hochberg,Peter A. Horn,Dominique P.V. de Kleijn,Lambros Kordelas,Boris W. Kramer,Eva-Maria Krämer-Albers,Sandra Laner-Plamberger,Saara Laitinen,Tommaso Leonardi,Magdalena J. Lorenowicz,Sai Kiang Lim,Jan Lötvall,Casey A. Maguire,Antonio Marcilla,Irina Nazarenko,Takahiro Ochiya,Tushar Patel,Shona Pedersen,Gabriella Pocsfalvi,Stefano Pluchino,Peter J. Quesenberry,Ilona G. Reischl,Francisco J. Rivera,Ralf Sanzenbacher,Katharina Schallmoser,Ineke Slaper-Cortenbach,Dirk Strunk,Torsten Tonn,Pieter Vader,Pieter Vader,Bas W.M. van Balkom,Marca H. M. Wauben,Samir El Andaloussi,Samir El Andaloussi,Clotilde Théry,Eva Rohde,Bernd Giebel +57 more
TL;DR: In this paper, the authors summarize recent developments and the current knowledge of extracellular vesicles (EVs) and discuss safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application.
Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine
TL;DR: Among MSCs, human uterine cervical stem cells (hUCESCs) may be a good candidate for obtaining secretome-derived products, and regulatory requirements for manufacturing and quality control will be necessary to establish the safety and efficacy profile of these products.
1.1K
Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications
TL;DR: Current knowledge related to the potential use of MSC-derived EVs in various diseases is reviewed and the promising future for EVs as an alternative, cell-free therapy is discussed.
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases.
TL;DR: Current understanding of the immunomodulatory mechanisms of MSCs and issues related to their therapeutic application are discussed, which suggest the plasticity of immunoregulation by M SCs is controlled by the intensity and complexity of inflammatory stimuli.
1K
References
Snail is required for transforming growth factor-β-induced epithelial–mesenchymal transition by activating PI3 kinase/Akt signal pathway
TL;DR: It is suggested phosphatidylinositol 3-OH kinase (PI3K)/Akt signaling is also necessary for TGF-beta-induced EMT in lens epithelial cells by showing that LY294002, an inhibitor of the p110 catalytic subunit of PI3K, blocked the expression of alpha-smooth muscle actin (alpha-SMA) and morphological changes.
Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model.
TL;DR: It is shown that MSCs secreted 40–100 nm particles, which have the typical characteristics of exosomes, and these MSC-derived exosome promoted migration of the breast cancer cell line MCF7.
Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited Cardioprotection in Polymicrobial Sepsis.
Xiaohong Wang,Haitao Gu,Dongze Qin,Dongze Qin,Liwang Yang,Liwang Yang,Wei Huang,Kobina Essandoh,Yigang Wang,Charles C. Caldwell,Tianqing Peng,Basilia Zingarelli,Guo-Chang Fan +12 more
TL;DR: Exosomal miR-223 plays an essential role for MSC-induced cardio-protection in sepsis, and is identified as a target for down-regulation of Sema3A and Stat3 in WT-exosomes.
Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease
TL;DR: The evidence supporting the hypothesis that transplanted MSCs secrete factors to reduce tissue injury and/or enhance tissue repair is reviewed including the recent identification of exosome as a therapeutic agent in MSC secretion.